With the normalization and institutionalization of national centralized drug procurement (NCDP) policy, a large number of generic drugs have been included in the clinical frontline, benefiting hundreds of millions of patients. At the same time, real-world studies (RWS) on generics and innovator drugs have been carried out successively, providing evidence-based support for the promotion and optimization of NCDP policy. This paper systematically reviewed the RWS of generic drugs in the past five years of the NCDP policy, discussed and summarized the evidence of clinical efficacy, safety and cost-effectiveness of major generic drugs such as anti-infective drugs, cardiovascular drugs, neuropsychotics, hypoglycemic drugs, and anti-tumor drugs, and analyzed the current RWS status of generic drugs. Overall, the clinical effectiveness and safety of domestic generic drugs are basically the same as that of the innovator drugs, and there is no statistically significant difference, while generic drugs are more cost-effective. Current research still reveals shortcomings in in data quality and integrity, standardization and rigor of research methods, study coverage and population diversity, pharmacoeconomic evaluation and long-term safety monitoring, which point out the direction for later research in this field. Through systematic integration and analysis of the RWS of generic drugs, this review is expected to improve public awareness and recognition of NCDP policy, and provide an important reference for promoting the in-depth implementation of NCDP policy.

1.Wang Z, Wang K, Hua Y, et al. Impact and implications of national centralized drug procurement in China[J]. Int J Clin Pharm, 2024, 46(6): 1557-1562. DOI: 10.1007/s11096-024-01767-1.

2.王少飞, 张勇, 冯伟忠. 药品集采政策与药企研发行为 [J]. 经济问题, 2025(1): 91-99. [Wang SF, Zhang Y, Feng WZ. Centralized drug procurement policy and R&D behavior of pharmaceutical companies[J]. On Economic Problems, 2025(1): 91-99.] DOI: 10.16011/j.cnki.jjwt.2025.01.010.

3.Gu Y, Zhuang Q. Does China's centralized volume-based drug procurement policy facilitate the transition from imitation to innovation for listed pharmaceutical companies? Empirical tests based on double difference model[J]. Front Pharmacol, 2023, 14: 1192423. DOI: 10.3389/fphar.2023.1192423.

4.Zhu Z, Wang Q, Sun Q, et al. Improving access to medicines and beyond: the national volume-based procurement policy in China[J]. BMJ Glob Health, 2023, 8(7): e11535. DOI: 10.1136/bmjgh-2022-011535.

5.Huang A, Wang X, Tao Y, et al. Healthcare professionals' knowledge, attitude and practice towards National Centralized Drug Procurement policy in central China: a cross-sectional study[J]. Front Pharmacol, 2022, 13: 996824. DOI: 10.3389/fphar.2022.996824.

6.Zhang W, Xu Q, Peng J, et al. Problems and challenges encountered by Chinese medical institutions in implementing the national centralized drug procurement[J]. Front Pharmacol, 2023, 14: 1233491. DOI: 10.3389/fphar.2023.1233491.

7.Li H, Lin F, Wang R, et al. The impacts of national centralized drug procurement policy on drug utilization of medical institutions: an empirical study in a county-level hospital in China[J]. BMC Health Serv Res, 2024, 24(1): 513. DOI: 10.1186/s12913-024-10964-7.

8.Hua Y, Lu J, Bai B, et al. Can the profitability of medical enterprises be improved after joining China's centralized drug procurement? A difference-in-difference design[J]. Front Public Health, 2022, 9: 809453. DOI: 10.3389/fpubh.2021.809453.

9.张兰, 董宪喆, 王之舟. 真实世界研究在国产仿制药临床疗效与安全性评价中的应用及展望[J]. 药物不良反应杂志, 2023, 25(3): 129-132. [Zhang L, Dong XZ, Wang ZZ. Application and prospect of real world study in clinical efficacy and safety evaluation of generic drugs[J]. Adverse Drug Reactions Journal, 2023, 25(3): 129-132.] DOI: 10.3760/cma.j.cn114015-20230103-01203.

10.马文昊, 王诗淳, 靳英辉, 等. 真实世界研究的发展与展望[J]. 中国循证心血管医学杂志, 2023, 15(10): 1266-1271. [Ma WH, Wang SC, Jin YH, et al. The development and prospect of real-world research[J]. Chinese Journal of Evidence-Based Cardiovascular Medicine, 2023, 15(10): 1266-1271.] DOI: 10.3969/j.issn.1674-4055.2023.10.29.

11.Hu H, Wang H, Ang L, et al. Patient-focused drug development and real world study[J]. Integr Med Res, 2025, 14(1): 101119. DOI: 10.1016/j.imr.2024.101119.

12.Berger ML, Sox H, Willke RJ, et al. Good practices for real-world data studies of treatment and/or comparative effectiveness: recommendations from the joint ISPOR-ISPE special task force on real-world evidence in health care decision making[J]. Value Health, 2017, 20(8): 1003-1008. DOI: 10.1016/j.jval.2017. 08.3019.

13.Klonoff DC. The new FDA real-world evidence program to support development of drugs and biologics[J]. J Diabetes Sci Techn, 2020, 14(2): 345-349. DOI: 10.1177/1932296819832661.

14.方碧陶. 国家药品监督管理局印发《真实世界证据支持药物研发与审评的指导原则（试行）》[J]. 中医药管理杂志, 2020, 28(2): 107. [Fang BT. The National Medical Products Administration has issued the "Guiding principles for drug research and evaluation supported by real-world evidence (Trial)"[J]. Journal of Traditional Chinese Medicine Management, 2020, 28(2): 107.] DOI: 10.16690/j.cnki.1007-9203.2020.02.047.

15.国家药品监督管理局药品审评中心. 用于产生真实世界证据的真实世界数据指导原则（试行）[EB/OL]. (2021-04-13) [2025-06-01]. https://www.cde.org.cn/main/news/viewInfoCommon/2a1c437ed54e7b838a7e86f4ac21c539.

16.国家药品监督管理局药品审评中心. 药物真实世界研究设计与方案框架指导原则（试行）[EB/OL]. (2023-02-16) [2025-06-01]. https://www.cde.org.cn/main/news/viewInfoCommon/14aac16a4fc5b5841bc2529988a611cc.

17.尹璇, 黄睿健, 伍俊妍, 等. 药品临床综合评价项目真实世界研究质量控制规范（2024版）[J]. 健康发展与政策研究, 2024, 27(5): 432-436. [Yin X, Huang RJ, Wu JY, et al. Guidelines for quality control in real-world studies of drug clinical comprehensive evaluation projects (version 2024)[J]. Health Development and Policy Research, 2024, 27(5): 432-436.] DOI: 10.12458/HDPR.202408073.

18.Knottnerus JA, Tugwell P. Real world research[J]. J Clin Epidemiol, 2010, 63(10): 1051-1052. DOI: 10.1016/j.jclinepi. 2010.08.001.

19.Lee B, Kim N, Won S, et al. Propensity score matching for comparative studies: a tutorial with R and Rex[J]. J Minim Invasive Surg, 2024, 27(2): 55-71. DOI: 10.7602/jmis.2024.27.2.55.

20.山东省医院协会药物经济学专业委员会. 集中带量采购政策下山东省调脂药物临床综合评价专家共识[J]. 中国药房, 2022, 33(15): 1793-1798. [Pharmacoeconomics Committee Of Shandong Association. Expert consensus on the comprehensive clinical evaluation of lipid- lowering drugs under the centralized drug volume-based procurement policy in Shandong Province[J]. China Pharmacy, 2022, 33(15): 1793-1798.] DOI: 10.6039/j.issn.1001-0408.2022.15.01.

21.江西省研究型医院学会, 江西省药学会药物流行病学专业委员会. 集中带量采购政策下江西省口服二氢吡啶类钙离子通道阻滞剂药品临床综合评价专家共识[J]. 中国现代应用药学, 2023, 40(23): 3334-3340. [Jiangxi Research Hospital Association, Pharmacoepidemiology Committee of Jiangxi Society. Expert consensus on the comprehensive clinical evaluation of oral dihydropyridine calcium channel blockers under the centralized drug volume-based procurement policy in Jiangxi province[J]. Chinese Journal of Modern Applied Pharmacy, 2023, 40(23): 3334-3340.] DOI: 10.13748/j.cnki.issn1007-7693.20223990.

22.国家组织药品集中采购中选仿制药疗效与安全性真实世界研究课题组. 国家集采仿制药疗效与安全性评价真实世界研究报告——以第二、三批集采为例[J]. 中国医疗保险, 2023, (10): 5-11. [The Real-world Research Group Procurement. Report of VBP-generics real world study on effectiveness and safety in China-taking the second and third batches as an example[J]. China Health Insurance, 2023, (10): 5-11.] DOI: 10.19546/j.issn.1674-3830.2023.10.001.

23.袁倩倩, 马月静, 刘莹, 等. 基于真实世界的集中带量采购品种注射用头孢呋辛钠预防剖宫产术后感染的临床再评价[J]. 中国医院用药评价与分析, 2024, 24(3): 275-277. [Yuan QQ, Ma YJ, Liu Y, et al. Clinical re-evaluation on centrally purchased cefuroxime sodium for injection in preventing infection after cesarean section: a real-world study[J]. Evaluation and Analysis of Drug-Use in Hospitals of China, 2024, 24(3): 275-277.] DOI: 10.14009/j.issn.1672-2124.2024.03.005.

24.宋沧桑, 邓雨琴, 刘璐, 等. 基于多中心真实世界数据的集采注射用头孢曲松治疗细菌性感染的临床综合评价[J]. 中国医院药学杂志, 2024, 44(5): 585-590, 597. [Song CS, Deng YQ, Liu L, et al. Comprehensive clinical evaluation of centralized procurement ceftriaxone for injection in the treatment of bacterial infections based on multicenter real-world data[J]. Chinese Journal of Hospital Pharmacy, 2024, 44(5): 585-590, 597.] DOI: 10.13286/j.1001-5213.2024.05.15.

25.刘琰, 于静, 刘欢, 等. 国家集中带量采购盐酸莫西沙星氯化钠注射液治疗社区获得性肺炎应用效果的真实世界研究 [J]. 中国医药导报, 2023, 20(26): 134-137. [Liu Y, Yu J, Liu H, et al. Real-world study on the application effect of national centralized acquisition with quantity of moxifloxacin hydrochloride sodium chloride injection in the treatment of community acquired pneumonia[J]. China Medical Herald, 2023, 20(26): 134-137.] DOI: 10.20047/j.issn1673-7210.2023.26.29.

26.庞婕, 吴晓雯, 李春华, 等. 中标与原研盐酸莫西沙星片治疗门诊社区获得性肺炎的有效性、安全性与经济性比较[J]. 中国药房, 2023, 34(2): 200-204. [Pang J, Wu XW, Li CH, et al. Comparison of efficacy, safety and economics of bid-winning and original moxifloxacin hydrochloride tablets in the treatment of outpatient community-acquired pneumonia[J]. China Pharmacy, 2023, 34(2): 200-204.] DOI: 10.6039/j.issn.1001-0408.2023. 02.14.

27.刘雨蒙, 熊堉, 胡琪, 等. 替加环素原研药和仿制药的有效性和安全性评价[J]. 中国医院药学杂志, 2022, 42(22): 2378-2382. [Liu YM, Hu Y, Hu Q, et al. Effeetiveness and safety evaluation of tigecycline for original and generie drug[J]. Chinese Journal of Hospital Pharmacy, 2022, 42(22): 2378-2382.] DOI: 10.13286/j.1001-5213.2022.22.11.

28.葛丽烨, 张静寅, 马维娜, 等. 国家组织药品集中带量采购政策下某院替加环素临床使用分析[J]. 中国药业, 33(10): 25-29. [Ge LY, Zhang JY, Ma WN, et al. Clinical application of tigecycline in a hospital under the policy of national-centralized drug procurement[J]. China Pharmaceuticals, 33(10): 25-29.] DOI: 10.3969/j.issn.1006-4931.2024.10.006.

29.兰艳, 舒成仁, 张松, 等. 集中带量采购政策背景下某院万古霉素临床应用分析[J]. 中国药业, 2023, 32(9): 109-112. [Lan Y, Shu CR, Zhang S, et al. Clinical application of vancomycin in a hospital under the background of the national centralized drug procurement policy[J]. China Pharmaceuticals, 2023, 32(9): 109-112.] DOI: 10.3969/j.issn.1006-4931.2023.09.026.

30.鲁虹, 史群志, 吴戈, 等. 基于治疗药物监测的注射用美罗培南省集采和进口品种的临床应用实践分析[J]. 中南药学, 2021, 19(7): 1493-1497. [Lu H, Shi QZ, Wu G, et al. Clinical application of meropenem for injection collected and imported varieties based on therapeutic drug monitoring[J]. Central South Pharmacy, 2021, 19(7): 1493-1497.] DOI: 10.7539/j.issn.1672- 2981.2021.07.045.

31.王琲, 应寅清, 张亮, 等. 带量采购中标仿制药利奈唑胺片与原研药有效性及安全性的真实世界研究[J]. 中国临床药学杂志, 2023, 32(1): 18-22. [Wang F, Ying YQ, Zhang L, et al. Real-world study of the efficacy and safety of generic linezolid tablets and branded one[J]. Chinese Journal of Clinical Pharmacy, 2023, 32(1): 18-22.] DOI: 10.19577/j.1007-4406.2023.01.004.

32.彭倩雯, 徐斌, 张伟霞. 急性冠脉综合征患者原研与“带量采购”阿托伐他汀钙片疗效和安全性的回顾性比较[J]. 药物流行病学杂志, 2023, 32(4): 361-366. [Peng QW, Xu B, Zhang WX. Retrospective comparison of the efficacy and safety of original and "drug volume-based purchasing" atorvastatin in patients with acute coronary syndrome[J]. Chinese Journal of Pharmacoepidemiology, 2023, 32(4): 361-366.] DOI: 10.19960/j.issn.1005-0698.202304001.

33.吴义来, 何银梅, 余建国, 等. 基于真实世界数据的阿托伐他汀钙片集采品种短期降脂效果、安全性及经济性评价 [J]. 齐齐哈尔医学院学报, 2024, 45(18): 1707-1712. [Wu YL, He YM, Yu JG, et al. Evaluation of short-term lipid-lowering effect, safety, and economics of centralized procured atorvastatin calcium tablets based on real-world data[J]. Journal of Qiqihar Medical University, 2024, 45(18): 1707-1712.] DOI: 10.3969/j.issn.1002-1256.2024.18.002.

34.韩嘉伦, 张翼, 林佰弟, 等. 中标对比原研氯吡格雷用于急性冠脉综合征患者经皮冠状动脉介入术后治疗的临床有效性及安全性研究[J]. 中国医院药学杂志, 2021, 41(6): 601-605. [Han JL, Zhang Y, Lin BD, et al. A comparative study on clinical efficacy and safety of generic versus originalclopidogrel in the treatment of acute coronary syndrome patients after percutaneous coronary intervention[J]. Chinese Journal of Hospital Pharmacy, 2021, 41(6): 601-605.] DOI: 10.13286/j.1001-5213.2021.06.08.

35.赵强, 石秀锦, 张翼, 等. 仿制和原研氯吡格雷在冠状动脉介入术后有效性、安全性和经济性的对比研究[J]. 中国药物应用与监测, 2021, 18(2): 74-78. [Zhao Q, Shi XJ, Zhang Y. A comparative study of efficacy, safety and economy between generic and original clopidogrel in patients undergoing percutaneous coronary intervention[J]. Chinese Journal of Drug Application and Monitoring, 2021, 18(2): 74-78.] DOI: 10.3969/j.issn.1672-8157.2021.02.002.

36.李一辰, 伊曼曼, 邵腾飞, 等. 集中带量采购替格瑞洛仿制药与原研药用于行支架辅助弹簧圈栓塞术颅内动脉瘤患者的有效性及安全性比较[J]. 中国临床药学杂志, 2024, 33(9): 661-666. [Li YC, Yi MM, Shao TF, et al. Comparison of efficacy and safety of generic and branded ticagrelor in patients with intracranial stent placement before and after the implementation of the centralized volume-based procurement policy[J]. Chinese Journal of Clinical Pharmacy, 2024, 33(9): 661-666.] DOI: 10.19577/j.1007-4406.2024.09.004.

37.缪阳, 孟中如, 祁旺, 等. 替格瑞洛集采中标药与原研药用于ACS患者PCI后的疗效与安全性比较[J]. 中国药房, 2024, 35(20): 2522-2526. [Miu Y, Meng ZR, Qi W, et al. Comparison of the efficacy and safety between the drug winning the bidding for centralized procurement and the original drug of ticagrelor in acute coronary syndrome patients after percutaneous coronary intervention[J]. China Pharmacy, 2024, 35(20): 2522-2526.] DOI: 10.6039/j.issn.1001-0408.2024.20.14.

38.叶伍飞, 刘俊, 赖伟华, 等. 阿哌沙班集中带量采购中选仿制药与原研药的临床疗效和安全性研究[J]. 中国医院用药评价与分析, 2024, 24(8): 919-922. [Ye WF, Liu J, Lai WH, et al. Clinical efficacy and safety of generic and original drugs in centralized drug volume-based procurement of apixaban[J]. Evaluation and Analysis of Drug-Use in Hospitals of China, 2024, 24(8): 919-922.] DOI: 10.14009/j.issn.1672-2124.2024.08.006.

39.果伟, 贾菲, 刘珊珊, 等. 仿制与原研舍曲林片疗效和安全性比较的真实世界研究[J]. 药物不良反应杂志, 2023, 25(3): 159-164. [Guo W, Jia F, Liu SS, et al. Real world study on the comparison of efficacy and safety of the generic and original sertraline tablets[J]. Adverse Drug Reactions Journal, 2023, 25(3): 159-164.] DOI: 10.3760/cma.j.cn114015-20221031-01011.

40.冯英楠, 董宪喆, 彭静, 等. 仿制与原研左乙拉西坦注射用浓溶液疗效、安全性与经济性比较的真实世界研究[J]. 药物流行病学杂志, 2024, 33(2): 152-157. [Feng YN, Dong XZ, Peng J, et al. Comparison of effectiveness, safety, and economy of generic and original levetiracetam concentrated solution for injection: a real-world study[J]. Chinese Journal of Pharmacoepidemiology, 2024, 33(2): 152-157.] DOI: 10.12173/j.issn.1005-0698.202312037.

41.Gaïes E, Jebabli N, Zerei S, et al. Comparing real-life carbamazepine exposure between innovator and generic formulation[J]. Therapies, 2022, 77(5): 523-526. DOI: 10.1016/j.therap.2022.01.017.

42.王可, 王之舟, 邢晓璇, 等. 盐酸普拉克索片集采中选仿制药与原研药疗效与安全性的真实世界比较研究[J]. 中国医院药学杂志, 2025, 45(5): 522-528. [Wang K, Wang ZZ, Xing XX, et al. Efficacy and safety evaluation of generic in volume-based procurement and original pramipexole dihydrochloride tablets: a real-world study[J]. Chinese Journal of Hospital Pharmacy, 2025, 45(5): 522-528.] DOI: 10.13286/j.1001-5213.2025.05.07.

43.李巍, 林明琼. 奥氮平片中标仿制药与原研药治疗效果与安全性的比较研究[J]. 中国现代医药杂志, 2025,27(1):62-65. [Li W, Lin MQ. A comparative study on the therapeutic efficacy and safety of generic drugs and original research drugs in olanzapine tablets[J]. Modern Medicine Journal of China, 2025,27(1):62-65.] DOI: 10.3969/j.issn.1672-9463.2025.01.012.

44.罗巧, 王之舟, 刘文娜, 等. 格列美脲集采中选仿制药与原研药临床效果的真实世界研究[J]. 中国药业, 2023,32(24):50-54. [Luo Q, Wang ZZ, Liu WN, et al. Clinical effects of bid-winning generic glimepiride in the centralized volume-based procurement and original-patented drugs: a real-world study[J]. China Pharmaceuticals, 2023,32(24):50-54.] DOI: 10.3969/j.issn.1006-4931.2023.24.012.

45.文志勇, 郭嘉豪, 杨雪明, 等. 仿制与原研维格列汀片治疗2型糖尿病有效性和安全性比较的真实世界研究[J]. 药物不良反应杂志, 2023,25(3):138-144. [Wen ZY, Guo JH, Yang XM, et al. Comparison of efficacy and safety of generic versus original vildagliptin tablets in type 2 diabetes mellitus: a real world study[J]. Adverse Drug Reactions Journal, 2023,25(3):138-144.] DOI: 10.3760/cma.j.cn114015-20221109-01041.

46.张歆, 周婧, 译丽则热·司马义, 等. 集采背景下恩格列净完整临床综合评价实践与思考[J]. 中国处方药, 2025, 23(2): 1-5. [Zhang X, Zhou J, Yilizere S, et al. Practice and reflection on the comprehensive clinical evaluation of empagliflozin under the background of centralized procurement[J]. Journal of China Prescription Drug, 2025, 23(2): 1-5.] DOI: 10.3969/j.issn.1671-945X.2025.02.001.

47.杨燕妮, 黎曙霞, 张晓娟, 等. 奥沙利铂集采药品安全性的真实世界研究[J]. 今日药学, 2024, 34(6): 451-454. [Yang YN, Li SX, Zhang XJ, et al. A real-world study on the safety of oxaliplatin drugs selected in the centralized procurement[J]. Pharmacy Today, 2024, 34(6): 451-454.] DOI: 10.12048/j.issn.1674-229X.2024.06.010.

48.陈喆, 石亚飞, 杨珺, 等. 仿制与原研卡培他滨的真实世界研究[J]. 中国医院用药评价与分析, 2023, 23(5): 531-534, 538. [Chen Z, Shi YF, Yang J, et al. Real-world study on generic and original capecitabine[J]. Evaluation and Analysis of Drug-Use in Hospitals of China, 2023, 23(5): 531-534, 538.] DOI: 10.14009/j.issn.1672-2124.2023.05.005.

49.伊佳, 钱石静, 赵新才, 等. 硼替佐米集采中选仿制药与原研药临床效果对比的真实世界研究[J]. 中国医疗保险, 2024(8): 20-25. [Yi J, Qian SJ, Zhao XC, et al. Real-world study on the clinical efficacy comparison between bid-winning generic and original drugs of bortezomib in the centralized procurement[J]. China Health Insurance, 2024(8): 20-25.] DOI: 10.19546/j.issn.1674-3830.2024.8.002.

50.王可, 董宪喆, 王之舟, 等. 替吉奥仿制药与原研药疗效与安全性的真实世界研究[J]. 实用药物与临床, 2023, 26(4): 340-346. [Wang K, Dong XZ, Wang ZZ, et al. Efficacy and safety evaluation of generic and original tegafur , gimeracil and oteracil porassium: a real-world study[J]. Practical Pharmacy and Clinical Remedies, 2023, 26(4): 340-346.] DOI: 10.14053/j.cnki.ppcr.202304011.

51.Zhang Y, Ren Y, Zheng Q, et al. The impact of national centralized drug procurement on health expenditures for lung cancer inpatients: a difference-in-differences analysis in a large tertiary hospital in China[J]. Front Public Health, 2022, 10: 956823. DOI: 10.3389/fpubh.2022.956823.

52.Si X, Huang L, Ding Q, et al. Comparison of clinical and economic evaluation between selected generic and original febuxostat tablets in Chinese gout patients with hyperuricemia: a real-world multicenter retrospective study[J]. Medicine, 2024, 103(4): e37081. DOI: 10.1097/MD.0000000000037081.

53.钱巧, 张宁, 朱恒波, 等. 奥美拉唑原研组和带量采购组在幽门螺杆菌感染根治中疗效、安全性及经济性分析[J]. 中南药学, 2024, 22(11): 3091-3095. [Qian Q, Zhang N, Zhu HB, et al. Efficacy, safety and economic analysis of omeprazole original drug and the volume-based procurement drug in the eradication of Helicobacter pylori infection[J]. Central South Pharmacy, 2024, 22(11): 3091-3095.] DOI: 10.7539/j.issn.1672-2981.2024.11.042.

54.李大双, 颜建周, 白铭钰, 等. 抗菌药物实施国家集中带量采购的政策效果分析[J]. 中国卫生经济, 2023, 42(5): 17-21. [Li DS, Yan JZ, Bai MY, et al. Analysis of the policy effeet of national drug centralized procurement for antibacterial drugs[J]. Chinese Health Economics, 2023, 42(5): 17-21.] DOI: 1003-0743(2023)05-0017-05.

55.陈泽, 姚祧, 金琛, 等. 某院执行国家药品集中带量采购政策对抗感染药物经济性及使用结构的影响[J]. 中国药师, 2024, 27(6): 1072-1081. [Chen Z, Yao T, Jin C, et al. Influence of national volume-based procurement policy on the economy and use structure of anti-infective drugs in a hospital[J]. China Pharmacist, 2024, 27(6): 1072-1081.] DOI: 10.12173/j.issn.1008-049X.202401232.

56.过佳月, 陈大宇, 张海霞. 集中带量采购政策相关的口服抗菌药物使用量及费用的中断时间序列分析[J]. 药学与临床研究, 2023, 31(4): 374-379. [Guo JY, Chen DY, Zhang HX. Changes in the use and cost of oral antimicrobials related to centralized volume-based procurement policy: an interrupted time-series analysis[J]. Pharmaceutical and Clinical Research, 2023, 31(4): 374-379.] DOI: 10.13664/j.cnki.pcr.2023.04.013.

57.宋雪, 黄哲, 杨坚, 等. 集中带量采购政策对辽宁省头孢菌素使用情况的影响分析[J]. 中国卫生事业管理, 2023, 40(2): 128-131, 152. [Song X, Huang Z, Yang J, et al. Analyzing on the influence of national centralized drug procurement policy on the use of cephalosporins in Liaoning province[J]. Chinese Health Service Management, 2023, 40(2): 128-131, 152.] DOI: 1004-4663(2023)02-128-05.

58.Zhang C, Ding Y, Wu Z, et al. Does China's competitive generic substitution policy deliver equivalent clinical outcomes? A pilot study with two generic formulations of olanzepine[J]. Front Pharmacol, 2023, 14: 1097600. DOI: 10.3389/fphar.2023.1097600.

59.Ma Y, Peng J, Yao X, et al. Access to anticancer medicines in public hospitals of Northwestern China[J]. Front Public Health, 2023, 11: 1182617. DOI: 10.3389/fpubh.2023.1182617.

60.乔元, 马方怡, 韩雨倍, 等. 我国药品临床综合评价相关案例评价机制及方法学探析[J]. 中国药房, 2025, 36(2): 146-153. [Qiao Y, Ma FY, Han YB, et al. Analysis of the evaluation mechanism and methodology of clinical comprehensive evaluation cases of drugs in China[J]. China Pharmacy, 2025, 36(2): 146-153.] DOI: 10.6039/j.issn.1001-0408.2025.02.03.

61.全筱筱, 熊文举, 潘军杰, 等. 基于大语言模型的数据查询机器人在医学领域的应用[J]. 医学新知, 2024, 34(9): 1057-1063. [Quan XX, Xiong WJ, Pan JJ, et al. Application of data query robots based on large language models in the medical field[J]. New Medicine, 2024, 34(9): 1057-1063.] DOI: 10.12173/j.issn.1004-5511.202312071.

62.Nguyen T, Debray TPA, Youn B, et al. Confounder adjustment using the disease risk score: a proposal for weighting methods[J]. Am J Epidemiol, 2024, 193(2): 377-388. DOI: 10.1093/aje/kwad196.

63.Maruszczyk K, Aiyegbusi OL, Cardoso VR, et al. Implementation of patient-reported outcome measures in real-world evidence studies: analysis of ClinicalTrials.gov records (1999-2021) [J]. Contemp Clin Trials, 2022, 120: 106882. DOI: 10.1016/j.cct.2022. 106882.